fcmedicineФундаментальная и клиническая медицинаFundamental and Clinical Medicine2500-07642542-0941КемГМУfcmedicine-70Research ArticleСтатьиНОВОЕ РУКОВОДСТВО ПО ПРОФИЛАКТИКЕ И ТЕРАПИИ НАРУШЕНИЙ БЕРЕМЕННОСТИ ПРОГЕСТАГЕНАМИA NEW GUIDELINE PROPOSAL FOR PREVENTION OR THERAPY OF PREGNANCY DISORDERS WITH PROGESTOGENSШиндлерАДОЛЬФSchindlerADOLF E.noemail@neicon.ruИнститут медицинских исследований и образованияРоссияInstitute for Medical Research and EducationRussian Federation201730122017245661Copyright © Шиндлер А.E., 20172017Шиндлер А.Schindler A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://fcm.kemsmu.ru/jour/article/view/70ReferencesSchindler AE, Carp H, Druckmann R, Genazzani AR, Huber J, Pasqualini J, et al. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol. 2015; 15:447-449.Schindler AE, Carp H, Druckmann R, Genazzani AR, Huber J, Pasqualini J, et al. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol. 2015; 15:447-449.Chinese Expert Consensus on use of progestogens for maintenance of early pregnancy and miscarriage management. Chin J Obstet Gynecol. 2016; 51(7): 481-485.Chinese Expert Consensus on use of progestogens for maintenance of early pregnancy and miscarriage management. Chin J Obstet Gynecol. 2016; 51(7): 481-485.Schindler AE, Campagnoli D, Druckmann R, Huber H, Pasqualini JR, et al. Classification and pharmacology of progestins. Maturitas. 2003; 46 (Suppl 1): S7-16.Schindler AE, Campagnoli D, Druckmann R, Huber H, Pasqualini JR, et al. Classification and pharmacology of progestins. Maturitas. 2003; 46 (Suppl 1): S7-16.Schindler AE. Progestogens for treatment and prevention of pregnancy disorders. Horm Mol Biol Clin Invest. 2010; 3: 453-460.Schindler AE. Progestogens for treatment and prevention of pregnancy disorders. Horm Mol Biol Clin Invest. 2010; 3: 453-460.Wahabi HA, Fayed AA, Esmail SA, Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011; 12: CD005943Wahabi HA, Fayed AA, Esmail SA, Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011; 12: CD005943Coomarasamy A, Williams E, Truchanowicz E, Seed P, Seed PT, Small R, et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015; 373:2141-2148.Coomarasamy A, Williams E, Truchanowicz E, Seed P, Seed PT, Small R, et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015; 373:2141-2148.Saraswat L, Bhattacharya S, Maheshwan A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: A systematic review. Br J Obstet Gynaecol. 2010; 117: 245-257.Saraswat L, Bhattacharya S, Maheshwan A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: A systematic review. Br J Obstet Gynaecol. 2010; 117: 245-257.Jauniauz E, Vav Oppenraaji RHF, Burton GJ. Obstetric outcome after early placental complications. Curr Opin Obstet Gynecol. 2010; 22: 452-457.Jauniauz E, Vav Oppenraaji RHF, Burton GJ. Obstetric outcome after early placental complications. Curr Opin Obstet Gynecol. 2010; 22: 452-457.Ahmed SR, El-Sammani M, Al-Sheeha MA, Aitallah AS, Jabin Khan F, Ahmed SR. Pregnancy outcome in women with threatened miscarriage: a year study. Mater Sociomed. 2012; 24: 26-28.Ahmed SR, El-Sammani M, Al-Sheeha MA, Aitallah AS, Jabin Khan F, Ahmed SR. Pregnancy outcome in women with threatened miscarriage: a year study. Mater Sociomed. 2012; 24: 26-28.Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized parallel, placebocontrolled trial. Fertil Steril. 2014; 102: 1357-1363.Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized parallel, placebocontrolled trial. Fertil Steril. 2014; 102: 1357-1363.Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol. 1990; 9: 149-154.Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol. 1990; 9: 149-154.Schindler AE. Prevention of preterm delivery with gestagens. Z Geburtshilfe Neonatol. 2004; 208(5): 165-169Schindler AE. Prevention of preterm delivery with gestagens. Z Geburtshilfe Neonatol. 2004; 208(5): 165-169Schindler AE. First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure. Gynecol Endocrinol. 2004; 18; 51-57Schindler AE. First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure. Gynecol Endocrinol. 2004; 18; 51-57Conde-Agualewa A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: Clinical and public health implications. Am J Obstet Gynecol. 2016: 214 (2); 235-242.Conde-Agualewa A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: Clinical and public health implications. Am J Obstet Gynecol. 2016: 214 (2); 235-242.Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016; 387(10033): 2106-2116.Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016; 387(10033): 2106-2116.Hudic I, Szekeres-Bartho J, Fatusic Z, Stray-Pedersen B, Dizdarević-Hudić L, Latifagić A, et al. Dydrogesterone supplementation in women with threatened preterm delivery-the impact on cytocine profile, hormone profile and progesterone induced blocking factor. J Reprod Immunol. 2011; 92: 103-107.Hudic I, Szekeres-Bartho J, Fatusic Z, Stray-Pedersen B, Dizdarević-Hudić L, Latifagić A, et al. Dydrogesterone supplementation in women with threatened preterm delivery-the impact on cytocine profile, hormone profile and progesterone induced blocking factor. J Reprod Immunol. 2011; 92: 103-107.Hudic I, Schindler AE, Szekeres-Bartho J, Stray-Pedersen B. Dydrogesterone and pre-term birth. Horm Mol Biol Clin Investig. 2016; 27(3): 81-83.Hudic I, Schindler AE, Szekeres-Bartho J, Stray-Pedersen B. Dydrogesterone and pre-term birth. Horm Mol Biol Clin Investig. 2016; 27(3): 81-83.Ragab M, Sammour MB, El-Kabarity H, Hegazy MR. Progesterone: A treatment for preeclamptic toxaemia. Ain Shams Med J; 1971; 22: 9-24.Ragab M, Sammour MB, El-Kabarity H, Hegazy MR. Progesterone: A treatment for preeclamptic toxaemia. Ain Shams Med J; 1971; 22: 9-24.Dalton K. Toxaemia of pregnancy treated with progesterone during the symptomatic stage. Br Med J. 1957; 2 (5041): 378-381.Dalton K. Toxaemia of pregnancy treated with progesterone during the symptomatic stage. Br Med J. 1957; 2 (5041): 378-381.Dalton K. Controlled trials in the prophylactic value of progesterone in the treatment of preeclamptic toxaemia. J Obstet Gynaecol Br Emp. 1962; 69: 463-468.Dalton K. Controlled trials in the prophylactic value of progesterone in the treatment of preeclamptic toxaemia. J Obstet Gynaecol Br Emp. 1962; 69: 463-468.Sammour MB, El-Makhzangy MN, Fawzy MM, Schindler A. Progesterone therapy in pregnancy induced hypertension: Therapeutic value and hormonal profile. Clin Exp Hypertens B. 1982; 1( Issue 4): 475-478.Sammour MB, El-Makhzangy MN, Fawzy MM, Schindler A. Progesterone therapy in pregnancy induced hypertension: Therapeutic value and hormonal profile. Clin Exp Hypertens B. 1982; 1( Issue 4): 475-478.Zainul Rashid MR, Lim JF, Nawawi NH, Lugman M, Zolkeplai MF, Rangkuty MS, et al. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in pregnancy. Gynecol Endocrinol. 2014; 30: 217-220.Zainul Rashid MR, Lim JF, Nawawi NH, Lugman M, Zolkeplai MF, Rangkuty MS, et al. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in pregnancy. Gynecol Endocrinol. 2014; 30: 217-220.Ali AB, Ahmad MF, Kwang NB, Shan LP, Shafie NM, Omar MH. Dydrogesterone support following assisted reproductive technique (ART) reduces the risk of pre-eclampsia. Horm Mol Biol Clin Invest. 2016; 27: 93-96.Ali AB, Ahmad MF, Kwang NB, Shan LP, Shafie NM, Omar MH. Dydrogesterone support following assisted reproductive technique (ART) reduces the risk of pre-eclampsia. Horm Mol Biol Clin Invest. 2016; 27: 93-96.Tskhay VB, Kovtun NM, Schindler AE. Successful prevention of preeclampsia in a high-risk pregnancy using progestogen dydrogesterone: a clinical case. Horm Mol Biol Clin Invest. 2016; 27: 85-88.Tskhay VB, Kovtun NM, Schindler AE. Successful prevention of preeclampsia in a high-risk pregnancy using progestogen dydrogesterone: a clinical case. Horm Mol Biol Clin Invest. 2016; 27: 85-88.
The authors declare that there are no conflicts of interest present.